Erica Herzog, MD, PhD
Research & Publications
Biography
News
Research Summary
My training as a physician scientist motivates me to seek new treatments for chronic lung diseases. I have spent more than 15 years pursuing this goal by studying the relationship mechanisms of fibrotic remodeling in the adult mammalian lung. My laboratory has had a sustained impact on the field of pulmonary fibrosis and is credited with several seminal discoveries that have been verified and reproduced in laboratories around the world. My early work helped ignite interest in role of innate immunity in lung injury, repair, and remodeling. We are also credited with providing new insight into the convergent and divergent mechanisms existing at the interface of lung injury and repair. More recent work focuses on how neuronal guidance proteins are involved in these processes, and in modeling the biophysical attributes of the normal and diseased adult lung. I am committed to training the next generation of Respiratory Scientists and in my close to 20 years at Yale have mentored numerous individuals at all stages of training and am currently accepting predoctoral students from YSM and GSAS.
Extensive Research Description
1. Role of the immune system in lung injury, repair, and remodeling. When I embarked upon my PhD during Pulmonary fellowship in 2001, pulmonary fibrosis was viewed as lacking an immunopathogenic component. My graduate work, however, determined that the recruitment and activation of bone marrow derived cells impacts injury, repair, and remodeling via paracrine orchestration of stromal responses. In fact, it was work from my lab, among others, that revitalized interest in how immunity orchestrates fibrotic injury and repair in the adult mammalian lung. We showed that the accumulation of innate immune cells such as macrophages or an ECM producing population of cells called fibrocytes could amplify critical events in fibrogenesis including TGFb1 activation, ECM production, and myofibroblast transformation; that that immune events in the lung could be monitored in the peripheral blood in many forms of human pulmonary fibrosis. We ultimately found that because fibrocytes were rare and difficult to detect in the blood, removal or repolarizing of macrophages is a more viable therapeutic strategy for fibrotic lung disease. These studies have been replicated and expanded by labs around the world and contributed to the preclinical portfolio for the short pentraxin protein PRM151, which recently met its primary endpoint in a Phase II trial.
2. Convergent and divergent mechanisms of injury and repair. Our work has contributed to the growing recognition that cells of the innate immune system display a highly plastic and adaptable phenotype through which they differentially regulate injury and fibrotic remodeling. For example, using the 18-glycolsyl hydrolase protein Chi3L1 as a prototype, we were able to show that a single gene product can simultaneously suppress or promote injury and fibrosis depending on its temporospatial expression in the disease process. We have also shown that danger associated molecular pathogens released by cells exposed to apoptotic, soluble, and mechanical stimuli signal to adjacent cells to initiate a repair program. Importantly, these mediators can be detected in the tissue of patients with various forms of pulmonary fibrosis, cementing the association with human disease. Finally, in very recent work, we have collaborated with investigators in Yale’s School of Immunobiology to describe a new innate immune process by which the inflammation associated hormone GDF15 (also called macrophage inhibitory cytokine 1) controls systemic inflammation and tissue responses via central regulation of peripheral tolerance in multiple organs.
3. Role of Neuronal Guidance Proteins. In delineating the processes described above, we discovered an unexpected contribution of neuronal guidance proteins (NGPs) to IPF and related diseases. In performing these studies we initially focused on NGP function at the so called “immune synapse” through which immune cells communicate. However, as the work has evolved we have observed that NGP function might also relate to their originally described role as regulators of nerve migration and remodeling. Ongoing work in my lab seeks to re-evaluate lung injury, inflammation, pathologic remodeling and repair in the context of macrophage mediated adrenergic nerve remodeling in experimentally induced mammalian lung fibrosis and in IPF.
4. Modeling the Lung Microenvironment. In studying the immune responses described above, we observed that cells that were thought to be terminally differentiated could be reprogrammed by their microenvironment to adopt new functional characteristics. While such an event had been suspected for a while, it became exceedingly evident in our collaboration with Laura Niklason’s lab when cells seeded into a decellularized lungs homed to their geospatial niche, assumed appropriate function, and engendered a living, breathing organ. When we applied this method to fibrotic lungs we observed that the biochemical and biophysical attributes of the lung microenvironment influence the adherence, survival, apoptosis, proliferation, fate specification, and transformation of fibroblasts; and that crosstalk with macrophages influences these endpoints in both animal models and in humans with several forms of lung fibrosis. Our studies revealed a new form of bidirectional feedback between macrophages, fibroblasts, and microenvironmental factors in health and disease that heavily depends upon biophysical cues.
Coauthors
Research Interests
Fibrosis; Lung; Lung Diseases, Interstitial; Bioengineering; Translational Research, Biomedical; Neuronal Outgrowth
Selected Publications
- Rational engineering of lung alveolar epitheliumLeiby K, Yuan Y, Ng R, Raredon M, Adams T, Baevova P, Greaney A, Hirschi K, Campbell S, Kaminski N, Herzog E, Niklason L. Rational engineering of lung alveolar epithelium Npj Regenerative Medicine 2023, 8: 22. PMID: 37117221, PMCID: PMC10147714, DOI: 10.1038/s41536-023-00295-2.
- Correction: Chitinase 1 regulates pulmonary fibrosis by modulating TGF-β/SMAD7 pathway via TGFBRAP1 and FOXO3Lee C, He C, Park J, Lee J, Kamle S, Ma B, Akosman B, Cotez R, Chen E, Zhou Y, Herzog E, Ryu C, Peng X, Rosas I, Poli S, Bostwick C, Choi A, Elias J, Lee C. Correction: Chitinase 1 regulates pulmonary fibrosis by modulating TGF-β/SMAD7 pathway via TGFBRAP1 and FOXO3 Life Science Alliance 2023, 6: e202302065. PMID: 37037591, PMCID: PMC10088146, DOI: 10.26508/lsa.202302065.
- Author Correction: Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organsWang W, Bale S, Wei J, Yalavarthi B, Bhattacharyya D, Yan J, Abdala-Valencia H, Xu D, Sun H, Marangoni R, Herzog E, Berdnikovs S, Miller S, Sawalha A, Tsou P, Awaji K, Yamashita T, Sato S, Asano Y, Tiruppathi C, Yeldandi A, Schock B, Bhattacharyya S, Varga J. Author Correction: Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs Nature Communications 2023, 14: 523. PMID: 36720888, PMCID: PMC9889748, DOI: 10.1038/s41467-023-36285-7.
- α1 Adrenoreceptor antagonism mitigates extracellular mitochondrial DNA accumulation in lung fibrosis models and in patients with idiopathic pulmonary fibrosisIshikawa G, Peng X, McGovern J, Woo S, Perry C, Liu A, Yu S, Ghincea A, Kishchanka A, Fiorini V, Hu B, Sun Y, Sun H, Ryu C, Herzog E. α1 Adrenoreceptor antagonism mitigates extracellular mitochondrial DNA accumulation in lung fibrosis models and in patients with idiopathic pulmonary fibrosis American Journal Of Physiology - Lung Cellular And Molecular Physiology 2023, 324: l639-l651. PMID: 36648147, PMCID: PMC10110730, DOI: 10.1152/ajplung.00119.2022.
- Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in PlantsMlakar L, Garrett S, Watanabe T, Sanderson M, Nishimoto T, Heywood J, Helke K, Pilewski J, Herzog E, Feghali-Bostwick C. Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants Biomedicines 2022, 10: 2861. PMID: 36359382, PMCID: PMC9687961, DOI: 10.3390/biomedicines10112861.
- Adaptive Immunity in Interstitial Lung DiseaseWinkler J, Herzog E. Adaptive Immunity in Interstitial Lung Disease 2022, 144-157. DOI: 10.1016/b978-0-08-102723-3.00018-4.
- Biobanking for Pulmonary, Critical Care, and Sleep MedicineWinkler J, Herzog E. Biobanking for Pulmonary, Critical Care, and Sleep Medicine 2020, 117-130. DOI: 10.1007/978-3-030-31507-8_9.
- GDF15 Is an Inflammation-Induced Central Mediator of Tissue ToleranceLuan HH, Wang A, Hilliard B, Carvalho F, Rosen CE, Ahasic A, Herzog E, Kang I, Pisani MA, Yu S, Zhang C, Ring A, Young L, Medzhitov R. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance Cell 2019, 178: 1231-1244.e11. PMID: 31402172, PMCID: PMC6863354, DOI: 10.1016/j.cell.2019.07.033.
- Plasma mitochondrial DNA is associated with extrapulmonary sarcoidosisRyu C, Brandsdorfer C, Adams T, Hu B, Kelleher DW, Yaggi M, Manning EP, Walia A, Reeves B, Pan H, Winkler J, Minasyan M, Dela Cruz CS, Kaminski N, Gulati M, Herzog EL. Plasma mitochondrial DNA is associated with extrapulmonary sarcoidosis European Respiratory Journal 2019, 54: 1801762. PMID: 31273041, PMCID: PMC8088542, DOI: 10.1183/13993003.01762-2018.
- The Prognostic Value of Monocyte Count in Idiopathic Pulmonary Fibrosis: A Multi-Omic Cohort StudyScott M, Quinn K, Li Q, Carroll R, Chen S, Carns M, Aren K, Sun J, Koloms K, Lee J, Kropski J, Zhao H, Herzog E, Martinez F, Moore B, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya J, Shah N, Khatri P. The Prognostic Value of Monocyte Count in Idiopathic Pulmonary Fibrosis: A Multi-Omic Cohort Study 2019, a7342-a7342. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7342.
- Circulating Mitochondrial DNA Is Associated with Fibroblast Activation and Disease Progression in Scleroderma Associated Interstitial Lung DiseaseRyu C, Sun H, Winkler J, Meena S, Walia A, Minasyan M, Brandsdorfer C, Gulati M, Peng X, Herzog E. Circulating Mitochondrial DNA Is Associated with Fibroblast Activation and Disease Progression in Scleroderma Associated Interstitial Lung Disease 2019, a7219-a7219. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7219.
- REPRODUCIBILITY AND OPTIMIZATION OF 18-FLUORO-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR EVALUATION OF CARDIAC SARCOIDOSISAlvi R, Young B, Shahab Z, Pan H, Winkler J, Herzog E, Miller E. REPRODUCIBILITY AND OPTIMIZATION OF 18-FLUORO-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR EVALUATION OF CARDIAC SARCOIDOSIS Journal Of The American College Of Cardiology 2019, 73: 1659. DOI: 10.1016/s0735-1097(19)32265-x.
- Physical and biochemical interactions drive fibrocytes accumulation in the scleroderma lung matrixSun H, Winkler J, Minasyan M, Pan H, Desai O, Pellowe A, Li J, Peng X, Gonzalez A, Herzog E. Physical and biochemical interactions drive fibrocytes accumulation in the scleroderma lung matrix 2018, lsc-1176. DOI: 10.1183/13993003.congress-2018.lsc-1176.
- Specific Pro-Inflammatory Signaling Pathways are Induced in Patients with Cardiac Sarcoidosis; Potential Prognostic/Therapeutic ApplicationsYoung B, Oatmen K, Freeburg L, Zellars K, Sapp A, Herzog E, Miller E, Spinale F. Specific Pro-Inflammatory Signaling Pathways are Induced in Patients with Cardiac Sarcoidosis; Potential Prognostic/Therapeutic Applications Journal Of Cardiac Failure 2018, 24: s10. DOI: 10.1016/j.cardfail.2018.07.033.
- Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial functionYu G, Tzouvelekis A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A, de Castro JPW, DeIuliis G, Ahangari F, Woolard T, Aurelien N, Arrojo e Drigo R, Gan Y, Graham M, Liu X, Homer RJ, Scanlan TS, Mannam P, Lee PJ, Herzog EL, Bianco AC, Kaminski N. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function Nature Medicine 2017, 24: 39-49. PMID: 29200204, PMCID: PMC5760280, DOI: 10.1038/nm.4447.
- Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary FibrosisRyu C, Sun H, Gulati M, Herazo-Maya J, Chen Y, Osafo-Addo A, Brandsdorfer C, Winkler J, Blaul C, Faunce J, Pan H, Woolard T, Tzouvelekis A, Antin-Ozerkis DE, Puchalski JT, Slade M, Gonzalez AL, Bogenhagen DF, Kirillov V, Feghali-Bostwick C, Gibson K, Lindell K, Herzog RI, Dela Cruz CS, Mehal W, Kaminski N, Herzog EL, Trujillo G. Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis American Journal Of Respiratory And Critical Care Medicine 2017, 196: 1571-1581. PMID: 28783377, PMCID: PMC5754440, DOI: 10.1164/rccm.201612-2480oc.
- SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosisTzouvelekis A, Yu G, Herazo-Maya J, Woolard T, Zhang Y, Lee H, Lee P, Herzog E, Bennett A, Kaminski N. SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis 2016, oa4979. DOI: 10.1183/13993003.congress-2016.oa4979.
- Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cellsTzouvelekis A, Yu G, Herazo-Maya J, Wang R, Werneck de Castro J, DeIuliis G, Ahangari F, Woolard T, Arrojo e Drigo R, Homer R, Srivastava A, Herzog E, Lee P, Bianco A, Kaminski N. Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells 2016, pa780. DOI: 10.1183/13993003.congress-2016.pa780.
- Analysis of Tissue Microenvironments Using Decellularized Mammalian TissuesSun H, Zhu Y, Herzog E. Analysis of Tissue Microenvironments Using Decellularized Mammalian Tissues 2016, 55-64. DOI: 10.1142/9789814678735_0005.
- Potential Mechanistic Links Between Aging and IPFPan H, Gulati M, Herzog E. Potential Mechanistic Links Between Aging and IPF 2015, 409-429. DOI: 10.1142/9789814635011_0016.
- Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2He C, Lee C, Dela Cruz C, Lee C, Zhou Y, Ahangari F, Ma B, Herzog E, Rosenberg S, Li Y, Nour A, Parikh C, Schmidt I, Modis Y, Cantley L, Elias J. Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2 Cell Reports 2015, 10: 1433. DOI: 10.1016/j.celrep.2015.02.017.
- Chitinase 3–Like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung FibrosisZhou Y, Peng H, Sun H, Peng X, Tang C, Gan Y, Chen X, Mathur A, Hu B, Slade MD, Montgomery RR, Shaw AC, Homer RJ, White ES, Lee CM, Moore MW, Gulati M, Lee CG, Elias JA, Herzog EL. Chitinase 3–Like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung Fibrosis Science Translational Medicine 2014, 6: 240ra76. PMID: 24920662, PMCID: PMC4340473, DOI: 10.1126/scitranslmed.3007096.
- Pulmonary FibrosisMurray L, Homer R, Gulati M, Herzog E. Pulmonary Fibrosis 2014, 2636-2653. DOI: 10.1016/b978-0-12-386456-7.05307-7.
- Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trialsSaketkoo L, Mittoo S, Huscher D, Khanna D, Dellaripa P, Distler O, Flaherty K, Frankel S, Oddis C, Denton C, Fischer A, Kowal-Bielecka O, LeSage D, Merkel P, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman R, Castelino F, Christmann R, Christopher-Stine L, Collard H, Cottin V, Danoff S, Highland K, Hummers L, Shah A, Kim D, Lynch D, Miller F, Proudman S, Richeldi L, Ryu J, Sandorfi N, Sarver C, Wells A, Strand V, Matteson E, Brown K, Seibold J, Aggarwal* R, Ainslie G, Alkassab F, Allanore Y, Descartes P, Anderson M, Andonopoulos A, Antin-Ozerkis D, Arrobas A, Ascherman* D, Assassi S, Baron M, Bathon* J, Behr J, Beretta L, Bingham C, Binnie M, Birring S, Boin F, Bongartz* T, Bourdin A, Bouros D, Brasington R, Bresser P, Buch M, Burge P, Carmona L, Carreira P, Carvalho C, Catoggio L, Chan K, Chapman J, Chatterjee S, Chua* F, Chung L, Conron M, Corte T, Cosgrove G, Costabel U, Cox G, Crestani B, Crofford L, Csuka M, Curbelo P, László C, Daniil Z, D'Arsigny C, Davis G, de Andrade J, De Vuyst P, Dempsey O, Derk C, Distler J, Dixon* W, Downey G, Doyle M, Drent M, Durairaj L, Emery P, Espinoza L, Farge D, Fathi M, Fell C, Fessler B, Fitzgerald J, Fox G, Foeldvari I, Frech T, Freitas S, Furst* D, Gabrielli A, García-Vicuña R, Georgiev O, Gerbino A, Gillisen A, Gladman D, Glassberg M, Gochuico B, Gogali A, Goh* N, Goldberg A, Goldberg H, Gourley* M, Griffing L, Grutters J, Gunnarsson R, Hachulla E, Hall F, Harari S, Herrick A, Herzog E, Hesselstrand R, Hirani N, Hodgson U, Hollingsworth H, Homer R, Hoyles R, Hsu V, Hubbard R, Hunzelmann N, Isasi M, Isasi E, Jimenez J, Johnson S, Jones C, Kahaleh B, Kairalla R, Kalluri M, Kalra S, Kaner R, Kinder B, Klingsberg R, Kokosi M, Kolb M, Kur-Zalewska J, Kuwana* M, Lake F, Lally E, Lasky J, Laurindo I, Able L, Lee P, Leonard C, Lien D, Limper A, Liossis S, Lohr K, Loyd J, Lundberg* I, Mageto Y, Maher T, Mahmud T, Manganas H, Marie I, Marras T, Martinez J, Martinez F, Mathieu A, Matucci-Cerinic* M, Mayes* M, McKown K, Medsger T, Meehan R, Cristina M, Meyer K, Millar A, Moğulkoç N, Molitor J, Morais A, Mouthon P, Müller V, Müller-Quernheim J, Nadashkevich O, Nador R, Nash P, Nathan S, Navarro C, Neves S, Noth I, Nunes H, Olson A, Opitz C, Padilla M, Pappas D, Parfrey H, Pego-Reigosa J, Pereira C, Perez R, Pope* J, Porter J, Renzoni E, Riemekasten G, Riley D, Rischmueller M, Rodriguez-Reyna T, Rojas-Serrano, Romam J, Rosen G, Rossman M, Rothfield N, Sahn S, Sanduzzi A, Scholand M, Selman M, Senécal J, Seo P, Silver* R, Solomon J, Steen* V, Stevens W, Strange C, Sussman R, Sutton E, Sweiss N, Tornling G, Tzelepis G, Undurraga A, Vacca A, Vancheri C, Varga J, Veale D, Volkov S, Walker U, Wencel M, Wesselius L, Wickremasinghe M, Wilcox P, Wilsher M, Wollheim F, Wuyts W, Yung G, Zanon P, Zappala C, Groshong S, Leslie K, Myers J, Padera R, Desai S, Goldin J, Kazerooni E, Klein J, Lynch D, Keen K. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials Thorax 2013, 69: 436. PMID: 24368713, PMCID: PMC3995282, DOI: 10.1136/thoraxjnl-2013-204202.
- Fibroblast engraftment in the decellularized mouse lung occurs via a β1-integrin-dependent, FAK-dependent pathway that is mediated by ERK and opposed by AKTSun H, Calle E, Chen X, Mathur A, Zhu Y, Mendez J, Zhao L, Niklason L, Peng X, Peng H, Herzog EL. Fibroblast engraftment in the decellularized mouse lung occurs via a β1-integrin-dependent, FAK-dependent pathway that is mediated by ERK and opposed by AKT American Journal Of Physiology - Lung Cellular And Molecular Physiology 2013, 306: l463-l475. PMID: 24337923, PMCID: PMC3949086, DOI: 10.1152/ajplung.00100.2013.
- Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2He C, Lee C, Dela Cruz C, Lee C, Zhou Y, Ahangari F, Ma B, Herzog E, Rosenberg S, Li Y, Nour A, Parikh C, Schmidt I, Modis Y, Cantley L, Elias J. Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2 Cell Reports 2013, 5: 1156. DOI: 10.1016/j.celrep.2013.11.016.
- Clinical and Imaging Features of BronchiectasisOliva I, Cortopassi F, Herzog E, Rubinowitz A. Clinical and Imaging Features of Bronchiectasis Clinical Pulmonary Medicine 2013, 20: 203-213. DOI: 10.1097/cpm.0b013e3182a2b233.
- Fibrocytes in Scleroderma Lung FibrosisReilkoff R, Mathur A, Herzog E. Fibrocytes in Scleroderma Lung Fibrosis 2012 DOI: 10.5772/26539.
- Fibrocytes in Scleroderma-Related Interstitial Lung DiseaseMathai S, Herzog E. Fibrocytes in Scleroderma-Related Interstitial Lung Disease 2011, 171-184. DOI: 10.1142/9789814343725_0010.
- TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid PMurray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, Gulati M, Homer RJ, Russell T, van Rooijen N, Elias JA, Hogaboam CM, Herzog EL. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P The International Journal Of Biochemistry & Cell Biology 2010, 43: 154-162. PMID: 21044893, DOI: 10.1016/j.biocel.2010.10.013.
- Tissue-Engineered Lungs for in Vivo ImplantationPetersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, Gavrilov K, Yi T, Zhuang ZW, Breuer C, Herzog E, Niklason LE. Tissue-Engineered Lungs for in Vivo Implantation Science 2010, 329: 538-541. PMID: 20576850, PMCID: PMC3640463, DOI: 10.1126/science.1189345.
- Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotypeMathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype Laboratory Investigation 2010, 90: 812-823. PMID: 20404807, PMCID: PMC3682419, DOI: 10.1038/labinvest.2010.73.
- Lack of a Fusion Requirement for Development of Bone Marrow-Derived EpitheliaHarris RG, Herzog EL, Bruscia EM, Grove JE, Van Arnam JS, Krause DS. Lack of a Fusion Requirement for Development of Bone Marrow-Derived Epithelia Science 2004, 305: 90-93. PMID: 15232107, DOI: 10.1126/science.1098925.
Clinical Trials
Conditions | Study Title |
---|---|
Immune System; Rheumatology/Scleroderma | Pathogenic Wnt-beta catenin target genes in macrophages and fibrosis |